Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

Also called NCT01584557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
Cardiovascular Clinical Sciences Inc (from the registry)
Registry
  • NCT NCT01584557
Other papers using this trial's data
  • Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload Journal of the American College of Cardiology, 2017-03-21 DOI, PubMed 28302292

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01584557. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2016-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
Acronym
Secret of CHF
Condition
Heart Failure
Intervention (Drug)
Tolvaptan or Samsca
Intervention (Drug)
placebo or sugar pill
Lead sponsor
Cardiovascular Clinical Sciences Inc (class: industry)

Record details

Record id
cardio:ct-nct01584557
Content hash
c1c88b1c5ab39ebe68626c39ab6ddff76d2caa26a51e9023049d1534fc10c1cc